Forsyth Barr highlights 'hidden gem' and growth opportunity at Ebos

Forsyth Barr highlights 'hidden gem' and growth opportunity at Ebos
Ebos has room to grow. (Image: Ebos)
Rebecca Howard
Ebos Group’s Australian Biotechnologies is a "hidden gem" while Transmedic offers a solid platform for future growth, Forsyth Barr analysts said.The two businesses represent about 15% of the group’s FY25 earnings before interest, taxes, depreciation and amortisation and “have higher organic growth than the group over the medium term”, Matt Montgomerie and Benjamin Crozier said.Both were initially acquired as part of its A$1.16 billion (NZ$1.25b)  LifeHealthcare acquisition, which was completed in May 2022....

More Markets

NZ sharemarket up 0.2%, 2% for the year
Markets Market Close

NZ sharemarket up 0.2%, 2% for the year

The S&P/NZX 50 Index closed at 13,377.85, up 32.88 points or 0.25%.

Graham Skellern 21 Oct 2025
Property for Industry says valuation cycle turning
Infrastructure

Property for Industry says valuation cycle turning

It cites strong occupancy, lease terms behind and sees strong 2026.

Staff reporters 21 Oct 2025
Meridian thinking big after Crown's offer to co-invest
Markets

Meridian thinking big after Crown's offer to co-invest

Govt pledge the biggest change to investment settings since listing in 2013.

Ian Llewellyn 21 Oct 2025
ANZ heads to court as select committee splits active litigation
Finance

ANZ heads to court as select committee splits active litigation

ANZ NZ consumer-finance case rumbles on as $300m settlement still on offer.

Andy Macdonald 21 Oct 2025